Top advances in esophageal/gastroesophageal junction cancers in 2021
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34140
Abstract: INTRODUCTION After almost a decade of limited progress in the treatment of esophagogastric cancer (EGC), which includes both esophageal squamous cell carcinoma (ESCC) and esophagogastric adenocarcinoma (EAC), groundbreaking improvements in clinically meaningful outcomes were made… read more here.
Keywords: cancers 2021; esophageal gastroesophageal; junction cancers; gastroesophageal junction ... See more keywords
Efficacy and safety of Nivolumab in patients with advanced esophageal, gastroesophageal, and gastric cancers: a meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2022 at "Immunopharmacology and Immunotoxicology"
DOI: 10.1080/08923973.2022.2117629
Abstract: Abstract Background Immune checkpoint inhibitors (ICI) have revolutionized care in oncology with improved overall survival in several cancer populations. Nivolumab has recently been approved for use in patients with upper gastrointestinal cancers. We quantitatively summarized… read more here.
Keywords: esophageal gastroesophageal; advanced esophageal; patients advanced; gastroesophageal gastric ... See more keywords
Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Oncology"
DOI: 10.1159/000510446
Abstract: Background: Trimodality therapy (TMT) with neoadjuvant chemoradiotherapy (nCRT) using concurrent carboplatin plus paclitaxel (CP) followed by surgery is the standard of care for locoregional esophageal or gastroesophageal junction (GEJ) cancers. Alternatively, nCRT with cisplatin plus… read more here.
Keywords: plus paclitaxel; esophageal gastroesophageal; chemoradiotherapy; gastroesophageal junction ... See more keywords
Predictors of clinical outcomes in patients undergoing curative treatment for esophageal or gastroesophageal junction adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e16067
Abstract: e16067 Background: Management of locally advanced esophageal and gastroesophageal junction (E/GEJ) adenocarcinoma is typically managed with neoadjuvant treatment followed by surgery. Clinical outcomes remain suboptimal and a considerable proportion of patients develop recurrence. However, prognostic… read more here.
Keywords: recurrence; esophageal gastroesophageal; treatment; gej adenocarcinoma ... See more keywords
Analyzing the impact of neoadjuvant radiation dose on pathologic response and survival outcomes in esophageal and gastroesophageal cancers.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of gastrointestinal oncology"
DOI: 10.21037/jgo.2019.02.18
Abstract: Background The optimal neoadjuvant radiation therapy (RT) dose prior to esophagectomy is unknown. We compared patients receiving lower-dose RT (LD-RT) of 41.4-45 Gy versus those receiving higher-dose RT (HD-RT) of 50-54 Gy. Methods Patients with… read more here.
Keywords: response; analyzing impact; esophageal gastroesophageal; neoadjuvant radiation ... See more keywords
(Neo)Adjuvant Treatment of Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma: Special Focus on Sex Differences
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14041088
Abstract: Simple Summary Multimodal therapy is standard in locally advanced esophageal and gastroesophageal adenocarcinoma. Although substantial differences in incidence and outcome between women and men have been observed, no clear sex-specific treatment guide has been developed.… read more here.
Keywords: locally advanced; esophageal gastroesophageal; gastroesophageal adenocarcinoma; advanced esophageal ... See more keywords